Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2005-05-27
2010-10-12
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S208100
Reexamination Certificate
active
07811577
ABSTRACT:
Methods of covalently-stabilizing alpha-helical, chimeric peptides constrained within a homotrimeric or heterotrimeric coiled-coil structure are disclosed. The coiled-coil structures made by the methods disclosed within this specification mimic all or a portion of the internal, trimeric coiled-coil motif contained within the fusogenic conformation of an enveloped virus membrane-fusion protein, particularly the internal coiled-coil domain of the HIV gp41 ectodomain. The HIV-derived, chimeric peptides disclosed comprise a non-HIV, soluble, trimeric form of a coiled-coil fused in helical phase to all or a portion of the N-helix of HIV gp41 and are covalently-stabilized in a homotrimeric or heterotrimeric coiled-coil structure through the formation of disulfide or chemoselective bonds between said peptides. The covalently-stabilized, HIV-derived, homotrimeric or heterotrimeric coiled-coil structures made by the methods disclosed herein represent a close mimetic of a HIV gp41 fusion intermediate and are potent inhibitors of HIV infectivity. These HIV-derived chimeric peptides may provide for therapeutic treatment against HIV infection by inhibiting the virus-host cell membrane fusion process.
REFERENCES:
patent: 5444044 (1995-08-01), Jiang et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5656480 (1997-08-01), Wild et al.
patent: 6150088 (2000-11-01), Chan et al.
patent: 6303317 (2001-10-01), Alber et al.
patent: 6506554 (2003-01-01), Chan et al.
patent: 6596497 (2003-07-01), Jiang et al.
patent: 6656906 (2003-12-01), Barney et al.
patent: 6716429 (2004-04-01), Sodroski et al.
patent: 6747126 (2004-06-01), Eckert et al.
patent: 6818740 (2004-11-01), Eckert et al.
patent: 6841657 (2005-01-01), Eckert et al.
patent: 6861059 (2005-03-01), Johnson et al.
patent: 7053179 (2006-05-01), Root et al.
patent: 2003/0219451 (2003-11-01), Sia et al.
patent: 2004/0213801 (2004-10-01), Wild et al.
patent: WO 94/02505 (1994-03-01), None
patent: WO 94/28920 (1994-12-01), None
patent: WO 96/40191 (1996-12-01), None
patent: WO 98/32848 (1998-07-01), None
patent: WO99/16883 (1999-04-01), None
patent: WO 00/06599 (2000-02-01), None
patent: WO 00/40616 (2000-07-01), None
patent: WO 01/03723 (2001-01-01), None
patent: WO 01/44286 (2001-06-01), None
patent: WO 02/24735 (2002-03-01), None
patent: WO 2003/052122 (2003-06-01), None
patent: WO 2005/058968 (2005-06-01), None
patent: WO 2005/118886 (2005-12-01), None
Louis, J. M., et al., 2001, Design and Properties of NCCG-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion Inhibitory Activity, J. Biol. Chem. 276(31):29485-29489.
Annis, Iona, et al., Methods in Enzymology, “Disulfide bond formation in peptides”, vol. 289, pp. 198-221, 1997.
Bewley, Carole A., et al., The Journal of Biological Chemistry, “Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41”, vol. 277, No. 16, pp. 14238-14245, 2002.
Blacklow, Stephen C., et al., Biochemistry, “A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein”, vol. 34, No. 46, pp. 14955-14962, 1995.
Borgia, Jeffrey A., et al., Tibtech Reviews, “Chemical synthesis of proteins”, vol. 18, pp. 243-251, 2000.
Bullough, Per A., et al., Nature, “Structure of influenza haemagglutinin at the pH of membrane fusion”, vol. 371, pp. 37-43, 1994.
Burton, Dennis R., et al., Proc. Natl. Acad. Sci. USA, “A vaccine for HIV type 1: The antibody perspective”, vol. 94, pp. 10018-10023, 1997.
Caffrey, Michael, et al., EMBO J., “Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41”, vol. 17, No. 16, pp. 4572-4584, 1998.
Cao, Jie, et al., J. Virology,“Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein”, vol. 67, No. 5, pp. 2747-2755, 1993.
Chan, David C., et al., Cell, “Core structure of gp41 from the HIV envelope glycoprotein”, vol. 89, pp. 263-273, 1997.
Chan, David C., et al., Proc. Natl. Acad. Sci, “Evidence that a prominent cavity in the coiled coil of HIV type I gp41 is an attractive drug target”, vol. 95, pp. 15613-15617, 1998.
Chan, David C., et al., Cell, “HIV entry and its inhibition”, vol. 93, pp. 681-684, 1998.
Chen, Chin-Ho, et al., J. Virology, “A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: Implication for viral fusion”, vol. 69, No. 6, pp. 3771-3777, 1995.
Cole, James L., et al., Biochemistry, “Thermodynamics of peptide inhibitor binding to HIV-1 gp41”, vol. 40, pp. 5633-5641, 2001.
Dong, Xiao-Nan, et al., Immunology Letters, “N- and C-domains of HIV-1 gp41: Mutation, structure and functions”, vol. 75, pp. 215-220, 2001.
Eckert, Debra M., et al., J. Mol. Biol., “Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues”, vol. 284, pp. 859-865, 1998.
Eckert, Debra M., et al., Cell, “Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket”, vol. 99, pp. 103-115, 1999.
Eckert, Debra M., et al., Annu. Rev. Biochem., “Mechanisms of viral membrane fusion and its inhibition”, vol. 70, pp. 777-810, 2001.
Eckert, Debra M., et al., PNAS, “Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region”, vol. 98, No. 20, pp. 11187-11192, 2001.
Eckhart, Leopold, et al., Journal of General Virology, “Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus”, vol. 77, pp. 2001-2008, 1996.
Erlanson, Daniel A., et al., PNAS, “Site-directed ligand discovery”, vol. 97, No. 17, pp. 9367-9372, 2000.
Farzan, Michael, et al., Journal of Virology, “Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain”, vol. 72, No. 9, pp. 7620-7625, 1998.
Fass, Deborah, et al.,Current Biology, “Dissection of a retrovirus envelope protein reveals structural similarity to influenza hemagglutinin”, vol. 5, No. 12, pp. 1377-1383, 1995.
Ferrer, Marc, et al., Nature Structural Biology, “Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements”, vol. 6, No. 10, pp. 953-960, 1999.
Furuta, et al., Nature Structural Biology, “Capture of an early fusion-active conformation of HIV-1 gp41”, vol. 5, No. 4, pp. 276-279, 1998.
Jiang, Shibo, et al., Nature, “HIV-1 inhibition by a peptide”,vol. 365, p. 113, 1993.
Jiang, Shibo, et al, Journal of Virology, “A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein”, vol. 72, No. 12, pp. 10213-10217, 1998.
Jiang, Shibo, et al., J. Virol. Methods, “A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody”, vol. 80, pp. 85-96, 1999.
Jiang, Shibo, et al., Biochemical and Biophysical Research Communications, “Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41”, vol. 269, pp. 641-646, 2000.
Joshi, Sangeeta Bagai, et al., Virology, “A core trimer of the paramyxovirus fusion protein: Parallels to influenza virus hemagglutinin and HIV-1 gp41”, vol. 248, pp. 20-34, 1998.
Judice, J. Kevin, et al., Proc. Natl. Acad. Sci., “Inhibition of HIV type 1 infectivity by constrained α-helical peptides: Implications for the viral fusion mechanism”, vol. 94, pp. 13426-13430, 1997.
Kilby, J. Michael, et al., Nature Medicine, “Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry”, vol. 4, No. 11
Bianchi Elisabetta
Bramhill David
Geleziunas Romas
Pessi Antonello
Heber Sheldon O.
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.
Merck Sharp & Dohme Corp.
Parkin Jeffrey S.
Wu Henry P.
LandOfFree
Covalently stabilized chimeric coiled-coil HIV gp41... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Covalently stabilized chimeric coiled-coil HIV gp41..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Covalently stabilized chimeric coiled-coil HIV gp41... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4208165